- Home
- FWRG vs COGT Comparison
FWRG vs COGT Comparison
Compare FWRG & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- COGT
- Stock Information
- Founded
- FWRG 1983
- COGT 2014
- Country
- FWRG United States
- COGT United States
- Employees
- FWRG N/A
- COGT N/A
- Industry
- FWRG Restaurants
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- COGT Health Care
- Exchange
- FWRG Nasdaq
- COGT Nasdaq
- Market Cap
- FWRG 1.0B
- COGT 1.0B
- IPO Year
- FWRG 2021
- COGT 2018
- Fundamental
- Price
- FWRG $16.86
- COGT $6.48
- Analyst Decision
- FWRG Strong Buy
- COGT Buy
- Analyst Count
- FWRG 10
- COGT 7
- Target Price
- FWRG $22.70
- COGT $14.17
- AVG Volume (30 Days)
- FWRG 794.8K
- COGT 1.0M
- Earning Date
- FWRG 03-11-2025
- COGT 05-06-2025
- Dividend Yield
- FWRG N/A
- COGT N/A
- EPS Growth
- FWRG N/A
- COGT N/A
- EPS
- FWRG 0.30
- COGT N/A
- Revenue
- FWRG $1,015,910,000.00
- COGT N/A
- Revenue This Year
- FWRG $18.22
- COGT N/A
- Revenue Next Year
- FWRG $13.49
- COGT N/A
- P/E Ratio
- FWRG $57.90
- COGT N/A
- Revenue Growth
- FWRG 13.95
- COGT N/A
- 52 Week Low
- FWRG $12.90
- COGT $5.88
- 52 Week High
- FWRG $25.98
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- FWRG 40.28
- COGT 38.02
- Support Level
- FWRG $16.17
- COGT $6.31
- Resistance Level
- FWRG $17.97
- COGT $7.49
- Average True Range (ATR)
- FWRG 0.89
- COGT 0.43
- MACD
- FWRG 0.10
- COGT -0.04
- Stochastic Oscillator
- FWRG 47.80
- COGT 10.90
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.